From: NK cell-based cancer immunotherapy: from basic biology to clinical development
 | Ligands |
---|---|
NK activating receptor | |
NKG2D | MHC class I chain-related protein A (MICA) and B (MICB), UL16-binding proteins (ULBP1-6) |
DNAM1 | PVR(CD155), nectin-2 (CD112) |
NKp30 (NCR3) | pp65, B7-H6, galectin-3, BAG6, viral hemagglutinin (HA), heparan sulfate (HS) glycosaminoglycans (GAGs), (DBL)-1a domain of Plasmodium falciparum erythrocyte membrane protein-1 |
NKp44 (NCR2) | PDGF-DD, 21spe-MLL5, PCNA, Syndecan-4, Nidogen-1, viral HA, HS GAGs |
NKp46 (NCR1) | Complement factor P, viral HA, HS GAGs, (DBL)-1a domain of Plasmodium falciparum erythrocyte membrane protein-1, vimentin |
CD16 (FcγRIII) | Fc portion of IgG antibodies |
NK inhibitory receptors | |
CD94/NKG2A | HLA-E |
KIR2DL1 | HLA-C, group 2 |
KIR2DL2/3 | HLA-C, group 1 |
KIR3DL1 | HLA-Bw4 |
KIR3DL2 | HLA-A3, A11 |